SAN DIEGO, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch of ...

There has been much buzz lately about the side effects of Apricus Bio’s (APRI) topically applied erectile dysfunction treatment, Vitaros. Vitaros is an alprostadil-based cream and stands as a ...

(Reuters) - Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug ...

(Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the ...

When looking for treatment for her eye condition, a woman was incorrectly given an erectile dysfunction cream to be used on her eyes, resulting in chemical injury. The woman was prescribed and ...

Apricus Biosciences has received European approval to market alprostadil 0.3% topical cream (Vitaros) for the treatment of erectile dysfunction (ED), the company announced today. Vitaros is a ...

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here. Apricus Biosciences, Inc. (NASDAQ : APRI), today announced the launch of ...

Apricus Biosciences, Inc.APRI announced that its topical cream, Vitaros for the treatment of erectile dysfunction (ED) has been launched in Lebanon by partner Elis Pharmaceuticals Ltd. Apricus' share ...

Apricus first launched Vitaros commercially six months ago in the UK, and followed up with Germany, Sweden, and Belgium. There has been some positive feedback from user experiences, followed up with ...

Ferring Pharmaceuticals purchased ex-U.S. assets and rights to Apricus Biosciences’ on-demand topical erectile dysfunction therapy cream Vitaros ® (alprostadil) for potentially $12.7 million. Ferring ...

* Co has lost $65 mln in market cap since Feb rejection of Vitaros (Adds details on options, background, shares) April 16 (Reuters) - Apricus Biosciences Inc said on Monday it was considering options ...